Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Trial ID or NCT#
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.
- - Allogeneic stem cell transplant recipient - Recipient or donor CMV seropositive - Have transplant engraftment - Able to swallow tablets
- - CMV organ disease - HIV infection - Use of other anti-CMV therapy post-transplant
Contact us to find out if this trial is right for you.
View on ClinicalTrials.gov